凝血因子Xa直接抑制剂的研究现状及应用(5)
 |
| 第1页 |
参见附件。
[17] Bohula May EA，Bonaca MP，Jarolim P，et al.Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome[J].Clin Chem，2014，60(1)：158-164.
[18] Komocs A，Vorobcsuk A，Aradi D，et al.New oral anticoagulants in acute coronary syndromes：what does a meta-analysis tell us？-Reply[J].JAMA Intern Med，2013，173(9)：835-836.
[19] Konishi N，Hiroe K，Kawamura M，et al.Differential effects of TAK-442，a novel orally active direct factor Xa inhibitor，and ximelagatran，a thrombin inhibitor，on factor V-mediated feedback on coagulation cascade and bleeding[J]. Thromb Haemost， 2010，104(3)：504-513.
[20] Scaglione F.New oral anticoagulants：comparative pharmacology with vitamin K antagonists[J].Clin Phar-macokinet，2013，52(2)：69-82.
[21] Oldgren J，Wallentin L，Alexander JH，et al.New oralanticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome：asystematic review and meta-analysis[J].Eur Heart J，2013，34(22)：1670-1680.
(收稿日期：2014-02-26)
您现在查看是摘要介绍页，详见PDF附件。